SAN DIEGO, June 16, 2011 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the
Company's Chief Executive Officer, Brian M.
Culley, will present at the OneMedForum Business Development
and Investment Conference on Thursday June
23rd, 2011, at 10:30am Eastern
time, in the Plaza Room at the Roosevelt Hotel in
New York.
Interested parties can access a live audio webcast and slide
presentation on the ADVENTRX Pharmaceuticals web site at
www.adventrx.com. An archived presentation will be available on the
web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company
focused on acquiring, developing and commercializing proprietary
product candidates. Two of the Company’s lead product candidates,
Exelbine™, or ANX-530 (vinorelbine injectable emulsion) and ANX-514
(docetaxel emulsion for injection), are novel emulsion formulations
of currently marketed chemotherapy drugs. The Company’s other lead
product candidate, ANX-188, is a novel, purified, rheologic and
antithrombotic compound, which initially is being developed as a
first-in-class treatment for pediatric patients with sickle cell
disease in acute crisis. More information can be found on the
Company’s web site at www.adventrx.com.
SOURCE ADVENTRX Pharmaceuticals, Inc.